These findings are similar to the recently reported trial of anti-LOXL-2 antibody, simtuzumab, in PSC, where 47/234 patients (20.1%) experienced a PSC-related event, with an overrepresentation of cholangitis (n = 31, or 13.2% of total cohort).29 This evidence concerns the gene LOXL2 and cholangitis.